Realbotix Q2 Revenue Plunges Amid Strategic AI Pivot; Nasdaq Listing via ONCO Expected
XBOTF sits 43% above its 52-week low of $0.175 on elevated volume (1.9× avg).
Summary
Realbotix reported Q2-2026 financial results showing a significant revenue decline to $225,000 and negative gross margins, attributed to a strategic pivot away from crypto operations. Despite the weak top-line, the company achieved positive comprehensive income due to one-time gains from debt repayment and asset sales. Management emphasized a shift to AI-integrated humanoid robotics, with new orders and deliveries not yet recognized in current revenue. Crucially, Realbotix announced its subsidiary is on track for a reverse takeover with Onconetix (ONCO) to list on the Nasdaq Capital Market by October 31, 2026. This Nasdaq listing plan is a major development for the OTC-traded company.
At the time of this announcement, XBOTF was trading at $0.25 on OTC in the Technology sector, with a market capitalization of approximately $57.2M. The 52-week trading range was $0.18 to $0.47. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.